Introduction
As agents targeting the type I insulin-like growth factor receptor (IGF-IR) are entering clinical trials, a more complete understanding of IGF-IR in human tumorigenesis is required. A recent review by Gualberto and Pollak (2009) indicates that at least 12 IGF-IR targeting compounds have entered clinical trials. These IGF-IR-targeting compounds include antibodies and small molecule inhibitors. The rationale behind targeting the IGF-IR stems from numerous studies showing elevated levels of IGF ligands and IGF-IR in a number of human cancers, the requirement for IGF-IR for transformation by a number of oncogenes, the association between circulating IGF levels and elevated cancer risk, and the association between adolescence growth rate (which is regulated in part by IGFs) and cancer risk (Arteaga and Osborne, 1989; Surmacz, 2000 Surmacz, , 2003 Sachdev and Yee, 2001; Chernicky et al., 2002; Baserga et al., 2003; Bohula et al., 2003; LeRoith and Roberts, Jr., 2003; Gualberto and Pollak, 2009 ). In addition, transgenic animal models have demonstrated that the overexpression of IGF-I, IGF-II or IGF-IR are sufficient to induce cancers in a number of tissues including the mammary gland (Bates et al., 1995; Bol et al., 1997; Pravtcheva and Wise, 1998; DiGiovanni et al., 2000; Hadsell et al., 2000; Moorehead et al., 2003; Carboni et al., 2005; Wilker et al., 2005; Wise and Pravtcheva, 2006; Jones et al., 2007; KaplanLefko et al., 2008; Linnerth et al., 2009) .
One limitation of targeted therapies is the development of resistance. This is particularly true for cell surface proteins, such as members of the epidermal growth factor receptor family such as epidermal growth factor receptor 1 and HER-2/Neu. Targeting HER-2/ Neu with Trastuzumab (Herceptin) initially induces tumor regression in a majority of patients with HER-2-positive breast tumors but ultimately the tumors in these patients become refractory to Trastuzumab and resume growth (Slamon et al., 2001) . Cell surface proteins are particularly susceptible to resistance as they lie upstream of a number of intracellular signaling molecules that mediate their physiologic effects. Mutations in these signaling molecules can negate the requirement for ligand-mediated receptor activation. In addition, different classes of cell surface receptors use similar intracellular signaling molecules to mediate their effects. Therefore, downregulation of intracellular signaling through targeting one cell surface receptor can be compensated by the upregulation of a different receptor by the tumor cells. This phenomenon has been observed in breast tumors that become refractory to Trastuzumab. Some trastuzumab resistant tumors express elevated levels of IGF-IR and IGF-IR activates ras, STAT, MAPK and PI-3K signaling similar to HER-2/ Neu (Lu et al., 2001; Nahta et al., 2005; Nahta and Esteva, 2006) .
Of the tumors that do respond, it remains unclear whether all of the tumors cells have been eradicated or whether residual tumor cells remain. Although this question is relevant to all types of cancer therapy it is particularly important to targeted therapies where less is understood about the optimal utilization of these therapies. If undetectable, dormant tumor cells remain despite a tumor being clinically non-detectable then cessation of the targeted therapy could lead to tumor recurrence. However, if all tumor cells are eradicated then the therapy could be halted without risk of tumor recurrence.
To address questions regarding the development of resistance to IGF-IR targeted therapies my laboratory developed an in vivo model of IGF-IR induced mammary tumorigenesis. This transgenic model, named MTB-IGFIR, expresses high levels of IGF-IR in mammary epithelial cells only in the presence of doxycycline which can be provided in the animal's food or water (Jones et al., 2007) . To model the effect of IGF-IR targeting agents, doxycycline was withdrawn from the food of MTB-IGFIR transgenic mice with established mammary tumors. A majority of the mammary tumors regressed to a non-palpable state when IGF-IR transgene expression was repressed (Jones et al., 2008) . This observation suggests that a large percentage of mammary tumors will initially regress to an undetectable state following the administration of an IGF-IR targeting agent. However, some of the tumors that initially regressed to a nonpalpable state eventually recurred suggesting that tumors initially responsive to IGF-IR targeting can become independent of IGF-IR signaling and would thus develop resistance to anti-IGF-IR agents (Jones et al., 2008) .
In this study, we examined mammary glands of mice in which IGF-IR transgene repression induced stable mammary tumor regression. Histologically, areas of tumor regression are still apparent 6-12 months after mammary tumors regressed to a non-palpable state and these lesions are characterized by cells, cell debris, lipofuscin and collagen. Interestingly, re-administration of doxycycline induces proliferation of mammary epithelial cells in the mammary gland and residing in the regressed lesions, indicating that residual cells capable of responding to IGF-IR signaling can remain dormant in the regressed tumor lesion. Moreover, re-expression of the IGF-IR transgene induced tumor development more rapidly in mice with regressed mammary tumors than in naı¨ve mice. Therefore, on the basis of our mouse model, IGF-IR targeting agents will induce stable tumor regression in a majority of breast cancer patients, however, changes in the mammary gland persist and render it susceptible to transformation. As residual tumor cells can lie dormant, these targeting agents will probably have to be administered throughout an individual's life to prevent the re-emergence of mammary tumors from dormant tumor cells.
Results

Residual tumor lesions are detectable after mammary tumor regression
The repression of the IGF-IR transgene, in mammary tumors induced by IGF-IR overexpression, resulted in the regression of a majority of the tumors. Although some of the mammary tumors were able to become independent of IGF-IR signaling and re-establish growth in the absence of elevated IGF-IR level (Jones et al., 2008) , over 80% of the tumors remained nonpalpable for at least 6 months. To determine whether these tumors completely disappeared, mammary tissue was collected from mice with regressed tumors that remained non-palpable for at least 6 months.
On macroscopic examination, the sites at which large mammary tumors were once present were clearly visible as small dark green or brown lesions within the mammary fat pad ( Figure 1a) . Histologically, the majority of residual lesions were characterized by the presence of large eosinophilic regions of cellular debris, some individual cells (but no clusters of tumor cells) and considerable amounts of a yellow-brown pigment that in some places had a crystalline appearance (Figures 1b and c) . It is possible that the yellowbrown pigment represented lipofuscin granules because lipofuscin granules have a yellow-brown appearance and are found in areas of cell destruction. Lipofuscin granules are lipid-based remnants of lysosomal degradation. To determine whether the yellow-brown pigment was in fact lipofuscin, Sudan black staining was performed. Some, but not all of the yellow-brown pigment in the regressed lesion stained black and thus some of this pigment is lipofuscin ( Figure 1d ). As the Sudan black-negative substance possessed a crystalline appearance, it was possible that this material within the regressed lesion was crystal of doxycycline. As doxycycline fluoresces, regressed lesions from unprocessed formalin-fixed, paraffin-embedded sections were visualized using an excitation wavelength of 596 nm and emission wavelength of 615 nm ( Figure 1e ). As the crystals in the regressed lesion strongly fluoresce, they are most likely doxycycline crystals. A Masson's trichrome stain revealed that the regressed lesions contained cell nuclei (black stain), collagen (blue stain) and little or no keratin or muscle fibers (red stain) (Figure 1f) . A small number of the regressed lesions differed from the ones described above in that they contained prominent cholesterol clefts with aggregates of lipid containing foamy macrophages (Figure 1g ), exhibited squamous differentiation (Figure1 h) or contained calcified material (Figure 1i ).
Of the 12 mice examined with stably regressed tumors, four mice contained mammary glands with small clusters of mammary tumor/epithelial cells (Figure 2a) . Some of the cells within these clusters stained positive for human IGF-IR, indicating that the IGF-IR transgene was being expressed independent of doxycycline ( Figure 2b ). The expression of IGF-IR transgene in the absence of doxycycline was observed in some of the tumors that recurred after doxycycyline withdrawal (Jones et al., 2008) . Three of the 12 mice with stable, regressed tumors contained areas of lobuloalveolar development (Figure 3a) . These alveolar epithelial cells did not express the IGF-IR transgene (Figure 3b ). There were some intensely staining cells near the alveolar epithelial cells but these cells are presumably mast cells as they stained positive with Toluidine blue (Figure 3c ) and stained positive in the absence of primary antibody, suggesting that the staining resulted from cellular peroxidase activity (Figure 3d Four of the MTB-IGFIR transgenic mice that contained tumors that regressed and remained non-palpable for over 6 months contained small regions of hyperplasia in their mammary glands. Hematoxylin and Eosin (H&E) staining revealed that these hyperplastic lesions were solid sheets of epithelial cells (a) and that all of these hyperplastic nodules expressed high levels of type I insulin-like growth factor receptor (IGF-IR) as determined by immunohistochemistry (b). Expression of IGF-IR could be found in some ducts with normal appearance (b; arrowhead), whereas other nearby epithelial cells did not express high levels of IGF-IR (b; arrow). Scale bars 100 mm. Figure 1 Characterization of regressed lesions. Mammary glands that contained large mammary tumors that regressed to a nonpalpable state still possessed macroscopic evidence of the previous tumor (a; arrow). Histologically, most of these regressed lesions contained eosinophilic regions of cell debris, some cells and a yellow-brown pigmented material (b, c). Soudan black staining (d) and fluorescence microscopy (e) indicated that some of the yellow-brown material was lipofuscin (d), whereas the rest was probably doxycycline crystals due to their ability to fluoresce (e). Masson's trichrome staining revealed that the regressed lesions also contained some collagen (blue stain) but no keratin or muscle (red stain). Some of the regressed lesions contained needle-shaped spaces of cholesterol clefts (g), squamous differentiation with pale eosinophilic ghost cells (h), or regions of mineralization (i) but these types of lesions were rare. Scale bars 100 mm for (b, d-i) and 20 mm for (c).
Residual tumor lesions contain cells capable of responding to the oncogenic effects of IGF-IR To determine whether these residual tumor lesions contained dormant tumor cells or were devoid of tumor cells, five MTB-IGF-IR transgenic mice with fully regressed lesions that remained non-palpable for at least 6 months were returned to doxycycline-supplemented food. Remarkably, tumor re-emergence rapidly occurred within an average of 9 days (range ¼ 7-12 days) after being re-induced with doxycycline ( Figure 4a ). This is significantly earlier than the 6-7 weeks of doxycycline administration required to initially induce mammary tumor development (Jones et al., 2007) . The tumors that developed after re-induction of elevated IGF-IR transgene expression resembled primary IGF-IR-induced tumors (solid sheets of epithelial cells) and overexpressed IGF-IR (Figures 4b and c) .
To determine whether the tumors that formed after re-induction of IGF-IR transgene expression could arise from the regressed lesions, MTB-IGFIR mice with stable regressed tumors were exposed to a 72-h pulse of doxycycline and then killed. Hematoxylin and eosin staining and IGF-IR immunohistochemistry demonstrated clusters of IGF-IR-positive cells within the regressed lesions (Figures 5a-d ) and in mammary ducts outside of the regressed lesions. A number of these cells were actively proliferating as indicated by positive staining for phosphorylated histone H3 (Figure 5e ). Therefore, there are cells within the regression lesion that contain the IGF-IR transgene that can probably re-initiate mammary tumorigenesis.
One additional interesting observation from the animals re-exposed to doxycycline for 72 h was the presence of transgene-expressing cells in apparently Figure 3 Three of the MTB-IGFIR transgenic mice that contained tumors that regressed and remained non-palpable for over 6 months contained regions of alveolar hyperplasia that were detectable after Hematoxylin and Eosin (H&E) staining (a). Epithelial cells within the hyperplastic nodules did not express high levels of type I insulin-like growth factor receptor (IGF-IR) as determined by immunohistochemistry (b). The few cells that did appear positive in the IGF-IR immunohistochemistry (b) are most likely mast cells (non-specific staining), as these cells appeared dark blue/purple after toluidine blue staining (c) and stain even in the absence of primary antibody (d). The lobuloalveolar cells stain strongly for b-casein (e, f), whereas the large ducts (* in e) or clusters of tumor cells (* in f) stain only weakly positive for b-casein. Scale bars 100 mm.
normal mammary ducts and in hyperplastic nodules. The IGF-IR-transgene expressing mammary epithelial cells can also be found in normal mammary ducts in mice treated with doxycycline for extended periods of time and have large mammary tumors. This observation would suggest that IGF-IR overexpression does not induce transformation in all mammary epithelial cells and IGF-IR overexpression requires additional modifications within cells or targets a particular type of cell in the mammary gland during transformation.
Discussion
As a number of IGF-IR-targeting agents are either entering, or are currently in early phase clinical trials, understanding how tumors will respond to this class of agents is required. Using our transgenic model of inducible IGF-IR-mediated mammary tumorigenesis, IGF-IR transgene was repressed in established mammary tumors to model the effects of IGF-IR-targeting agents. Our previous studies have shown that removal of doxycycline from MTB-IGFIR transgene mice resulted in IGF-IR downregulation, inhibition of IGF-IR phosphorylation and repression of IGF-IR-mediated signaling (Jones et al., 2009) . Therefore, repression of IGF-IR transgene induces similar responses that IGF-IR-targeting agents would, namely IGF-IR receptor downregulation and/or inhibition of IGF-IR-mediated signaling.
The first interesting observation from our study was the detectable evidence of prior mammary tumorigenesis even in mice tumors of which had been non-palpable for over 6 months. This observation suggests that the body is unable to completely restore tissue architecture to its pre-tumor state. The inability to complete repair and restore tissue architecture after tumor regression may have important implications for tumor recurrence. The residual lesions may contain dormant tumor cells, activated fibroblasts, altered extracellular matrix or vascular scaffolds that predispose the animal to tumor recurrence (Ghajar and Bissell, 2008; Denys et al., 2009; Pure, 2009) . In humans, only a limited number of studies have examined residual breast lesions at the histological level after therapy. One study examined 36 patients treated with doxorubicin and cyclophosphamide with or without the addition of bevacizumab (Bahri et al., 2009 ). On completion of therapy the patients underwent surgery and the residual tumor lesions were examined histologically and classified into three groups: (1) complete response showing no tumor cells, (2) nodular pattern showing confined cancer nodules and (3) small nodules or scattered cancer cells in large fibrotic regions. The lesions observed in our study most closely resemble the group 1 lesions in that the lesions contained large amounts of acellular stroma, a few immune cells and no detectable tumor cells (Figures 1b and c) . One other study (Peintinger et al., 2008) and a case report (Morris et al., 2010) in humans showed that breast tumor lesions after therapy present Figure 4 Fully regressed tumors can recur after forced reactivation of type I insulin-like growth factor receptor (IGF-IR). Tumor growth curve depicting rapid tumor re-growth in five mice that were re-induced with doxycycline after a period of more than 6 months in which the primary tumor had regressed to a non-palpable state (a). Hemtoxylin and eosin (H&E) (b) and IGF-IR immunohistochemistry (c) of a recurrent tumor that developed in a mouse after 7 days of doxycycline treatment. These tumors re-appeared as solid sheets of epithelial cells that stained positive for IGF-IR and were indistinguishable from primary mammary tumors that develop in MTB-IGFIR mice. Scale bars 100 mm.
with large amounts of acellular stroma and varying number of tumor cells. Therefore, the lesions observed in our MTB-IGFIR transgenic mice after IGF-IR downregulation share similar features with post-treatment breast tumors in humans.
The second interesting observation was the rate at which tumors reappeared after re-expression of the IGF-IR transgene. The overexpression of IGF-IR produced palpable mammary tumors in approximately 9 days in mice with regressed mammary tumors, whereas IGF-IR overexpression required approximately 44 days to produce the initial mammary tumors in naı¨ve mice. This has important implications for the clinical use of IGF-IR-targeted therapies in that these therapies may require life-long administration because halting the administration of IGF-IR-targeting agents would permit re-expression of the IGF-IR and eventually tumor recurrence. It remains unclear why tumors from mice with regressed tumor lesions grow faster after IGF-IR overexpression than naı¨ve mammary epithelial cells, but it could be due to the presence of altered fibroblasts or extracellular matrix as both have been implicated as important regulators of tumorigenesis (Ghajar and Bissell, 2008; Denys et al., 2009; Pure, 2009 ). This altered environment in conjunction with dormant tumor cells could facilitate the rapid re-appearance of tumors after IGF-IR re-expression.
The significance of the presence of lobuloalveoli in the mammary glands of virgin mice remains unclear. A search of the literature did not reveal any reports of lobuloalveolar development in virgin females with breast cancer or after breast cancer therapy. However, a study in transgenic mice using doxycycline-inducible expression of a c-myc transgene in immature osteoblasts demonstrated that c-myc overexpression resulted in the development of osteogenic sarcomas, whereas repression of c-myc in these osteogenic sarcomas lead to the differentiation of some of the tumor cells into mature osteocytes (Jain et al., 2002) . Therefore, the presence of lobuloalveoli in the mammary gland of virgin female Figure 5 After a 72-h pulse of doxycycline, MTB-IGFIR transgenic mice that contained tumors that regressed and remained non-palpable for over 6 months showed evidence of epithelial hyperplasia emanating from the regressed lesions. Two representative hematoxylin and eosin (H&E)-stained images are presented in (a, c). These regions of epithelial hyperplasia in the regressed lesions stained positive for type I insulin-like growth factor receptor (IGF-IR) as determined by immunohistochemistry (b, d) and a number of the cells stained positive for the proliferative marker phosphorylated histone H3 (e). Scale bars 100 mm (a, c, e) and 33 mm (b, d).
mice, which previously harbored mammary tumors before IGF-IR downregulation, may be formed from the differentiation of mammary tumor cells into lobuloalveolar cells. In support of this finding, lobuloaveoli have only been observed after tumor regression induced by IGF-IR downregulation and never in mammary glands exposed to either transient or persistent IGF-IR overexpression. Interestingly, these lobuloalveoli stained positive for b-casein, indicating that they have functional characteristics similar to alveolar epithelial cells. Although studies describing the differentiation of mammary tumors into lobuloalveoli in humans after traztuzamab therapy have not yet been described, the epidermal growth factor receptor inhibitor, erlotinib, has been shown to convert mammary tumor cells from a mesenchymal phenotype to an epithelial phenotype (Zhang et al., 2009) . In addition, the differentiation of acute promyeloid leukemias induced by all-trans retinoic acid is curative for many patients (Miranda et al., 2008) . Therefore, IGF-IRtargeting agents may promote differentiation of mammary tumor cells in addition to inducing tumor cell death.
In summary, most of the large solitary mammary tumors regress to a non-palpable state after IGF-IR transgene downregulation, however, the regions of previous tumorigenesis are not completely remodeled and alterations to the stromal environment persist. As tumors rapidly re-emerge after the re-overexpression of IGF-IR, the mammary glands that previously harbored mammary tumors probably contains dormant tumor cells waiting for the appropriate environment to recur. Therefore, the use of IGF-IR-targeting agents in human breast cancer may improve the treatment of breast tumors that express high levels of IGF-IR, but may not completely eradicate all tumor cells or completely restore the stromal alterations that may render the patients' breast tissue susceptible to subsequent mutagenic effects.
Materials and methods
Mice
The generation of MTB-IGFIR transgenic mice has been previously described (Jones et al., 2007) . To induce transgene expression, standard rodent chow was replaced with rodent chow containing 2 g/kg of doxycycline (Bio-Serv, Frenchtown, NJ, USA). Transgene repression was facilitated by the replacement of doxycycline-supplemented rodent chow with unsupplemented rodent chow. Tumor diameters were measured using digital calipers. All mice were maintained following the guidelines of the Canadian Council on Animal Care.
Histology and immunohistochemistry
Histology and immunohistochemistry were performed as previously described (Jones et al., 2007) . Anti-IGF-IR antibody (R&D systems, Minneapolis MN, USA) was used at a 1:100 dilution, whereas the anti-b-casein antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used at a 1:4000 dilution and the anti-phosphorylated histone H3 antibody (Abcam, Cambridge, MA, USA) was used at a 1:200 dilution.
Toluidine blue staining Formalin-fixed, paraffin-embedded 5-mm tissue sections were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol. Sections were stained for 3 min in a working solution of toluidine blue. The working solution of toluidine blue consisted of 5 ml of 1 g of toluidine blue O powder (Sigma, St Louis, MO, USA) and 45 ml of 1% sodium chloride (pH 2.3). After staining in toluidine blue, the sections were washed thrice in distilled water and then dehydrated through 95% alcohol and two changes of 100% alcohol. Sections were cleared with two changes (3 min each) of xylene and then mounted under a coverslip with permount (Fisher Scientific, Whitby, ON, Canada). This procedure stains mast cells dark blue/purple and all other cells light blue.
Doxycycline immunofluorescence
Doxycycline immunofluorescence was visualized on unprocessed, formalin-fixed, paraffin-embedded 5-mm tissue sections using a Texas red filter on an Olympus BX51 fluoresence microscope (Olympus Canada, Markham, ON, Canada).
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